U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Custom Compounding Center - 481888 - 10/28/2020
  1. Warning Letters

CLOSEOUT LETTER

Custom Compounding Center MARCS-CMS 481888 —

Delivery Method:
VIA Electronic Mail
Product:
Drugs
Recipient:
Recipient Name
Mark W. Shinabery
Recipient Title
Owner and Pharmacist-In-Charge
Custom Compounding Center

11700 Kanis Rd
Suite 1
Little Rock, AR 72211
United States

Mark@customccrx.com
Issuing Office:
Office of Pharmaceutical Quality Operations, Division II

United States

Mr. Shinabery:

The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter 2016-DAL-WL-14, dated March 16, 2016. We acknowledge that your firm no longer produces sterile drug products. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.

You are expected to take all necessary steps to ensure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/
CDR John W. Diehl, M.S.
Director, Compliance Branch
Office of Pharmaceutical Quality Operations,
Division II

Back to Top